UPDATE — Longeveron Provides Corporate Update and Announces 2023 Strategic Priorities and Anticipated Milestones
– Expects to enroll first patient in Phase 2 clinical trial of Lomecel-B™ for Aging-Related Frailty…
News
CES 2023: INFINIQ Demonstrates its Latest Sensor Fusion Annotation and Anonymization Technology Optimized for Autonomous Driving
SEOUL, South Korea–(BUSINESS WIRE)–#AIDataCompany—INFINIQ demonstrated its sensor fusion annotation technology at the CES 2023 with…
Quectel Demonstrates ASIL Solution for Advanced Automotive Applications at CES 2023
LAS VEGAS–(BUSINESS WIRE)–CES – Quectel Wireless Solutions, a leading global IoT solutions provider, today demonstrates…
Quectel Continues to Drive Digital Transformation With Advanced Smart Module, Edge Intelligence and Machine Vision Technologies at CES 2023
LAS VEGAS–(BUSINESS WIRE)–CES – Quectel Wireless Solutions, a global IoT solutions provider, is today demonstrating…
Harris Williams Advises The InterMed Group on its Sale to Cressey & Company LP and Health Enterprise Partners
RICHMOND, Va.–(BUSINESS WIRE)–Harris Williams, a global investment bank specializing in M&A advisory services, announces it…
Encore Bancshares, Inc. and Encore Bank Announce New Board Members
LITTLE ROCK, Ark.–(BUSINESS WIRE)–#BuildingSomethingDifferent–Encore Bancshares, Inc. and its wholly-owned bank subsidiary, Encore Bank, are pleased…
4 New Contracts for 8 Machines to Kick Off New Year at Knightscope (Nasdaq: KSCP)
Public Safety Innovator Continues Building Strong Growth Curve MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–$KSCP #SecurityRobot—Knightscope, Inc. (Nasdaq:…
First Business Bank Announces Leadership Promotions
— Internal Appointments Reflect Depth of Long-Tenured Leadership Team — MADISON, Wis.–(BUSINESS WIRE)–First Business Financial…
Longeveron Provides Corporate Update and Announces 2023 Strategic Priorities and Anticipated Milestones
– Expects to enroll first patient in Phase 2 clinical trial of Lomecel-B™ for Aging-Related Frailty…
Celularity’s Placental-Derived Allogeneic Cell Therapy Provides Clinically Meaningful Benefit and Durable Biological Effect in Patients with Moderate to Severe Crohn’s Disease in Phase 1, Phase 1b/2a and Phase 1b Studies
Legacy studies employing a single treatment course of two infusions seven days apart demonstrated greatest benefit…
Nexcella, Inc. Announces Additional Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in Relapsed/Refractory AL Amyloidosis Patients, Duration of Response Not Yet Reached
NXC-201 treatment continues to demonstrate 100% complete response rate in 6 relapsed/refractory AL amyloidosis patients…
Immix Biopharma Subsidiary Nexcella, Inc. Announces Additional Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in Relapsed/Refractory AL Amyloidosis Patients, Duration of Response Not Yet Reached
NXC-201 treatment continues to demonstrate 100% complete response rate in 6 relapsed/refractory AL amyloidosis patients…
Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis
As previously reported, resmetirom demonstrated improvements in NASH and liver fibrosis on liver biopsies, the…
Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
– Potential FDA approval anticipated in first quarter 2024, assuming the filing is accepted by…
Icosavax Provides Corporate Update and Anticipated Milestones for 2023
– Recently reported positive six-month immunogenicity data for IVX-121 against RSV; first clinical evidence of…
Aquestive Therapeutics Provides Business Update and Outlines Key 2023 Objectives
Anticipates commencing pivotal pharmacokinetic (PK) trial for AQST-109 (epinephrine sublingual film) in second half of…
Recludix Pharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 06, 2023 (GLOBE NEWSWIRE) — Recludix Pharma, a leader in platform approaches…
Ocular Therapeutix™ Provides 2022 Year End Corporate Update and Reviews Expected 2023 Milestones
Dextenza® Net Product Revenue in the Fourth Quarter of 2022 is Estimated to be $13.6…
TG Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Presentation scheduled for Monday, January 9, 2023 at 9:45 AM PT NEW YORK, Jan. 06,…
BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study
Hamsters infected with SARS-COV-2 and then treated with BiondVax’s inhaled anti-COVID-19 nanosized antibodies (NanoAbs) had…